Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes

Diabetic Medicine

Volumn 19, Issue 3, 2002, Pages 201-211

  Colhoun, H M ^a   Thomason, M J ^a   Mackness, M I ^b   Maton, S M ^c   Betteridge, D J ^d   Durrington, P N ^b   Hitman, G A ^e   Neil, H A W ^f   Fuller, J H ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Atorvastatin; CARDS; Diabetes; Lipid lowering; Trial

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC RETINOPATHY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; HYPERTENSION; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MORBIDITY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; HEPTANOIC ACIDS; HUMANS; LIPIDS; LIPOPROTEINS; MIDDLE AGED; PATIENT SELECTION; PLACEBOS; PYRROLES; RESEARCH DESIGN;

EID: 0036224827     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.2002.00643.x     Document Type: Article

References (41)

1. Morbidity and mortality in diabetics in the Framingham population. Sixteen-year follow-up study
2. Long-term prognosis after myocardial infarction in men with diabetes
3. Mortality and morbidity during a five-year follow-up of diabetics with myocardial infarction
4. International variations in cardiovascular mortality associated with diabetes mellitus; the WHO Multinational Study of Vascular Disease in Diabetes
5. Lipids, diabetes and vascular disease: The time to act
6. Proteinuria and mortality in diabetes: The WHO Multinational Study of Vascular Disease in Diabetes
7. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects
8. Retinopathy predicts coronary heart disease events in NIDDM patients
9. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS 23)
10. Diabetes and glucose tolerance as risk factors for cardiovascular disease: The Framingham Study
11. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial
12. Lipoprotein abnormalities in well-treated type II diabetic patients
13. Cholesterol lowering with Simvastatin improves prognosis of diabetic patients with coronary heart disease
14. Prevention of cardiovascular events and death with Pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
15. Cardiovascular events and their reduction with Pravastatin in diabetic and glucose intolerant myocardial infarction survivors with average cholesterol levels
16. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
17. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
18. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia
19. Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults
20. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II)
21. Dietary guidelines for healthy American adults. A statement for physicians and health professionals by the Nutrition Committee, American Heart Association
22. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
23. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes
24. UK Prospective Diabetes Study 16 overview of 6 years' therapy of Type II diabetes: A progressive disease
25. The WHO Multinational Study of Vascular Disease in Diabetics - Mortality follow-up
26. Clinical trial methodology
27. Diabetes Intervention Study. Multi-intervention trial in newly diagnosed NIDDM
28. Cardiovascular outcomes in Type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: The St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study
29. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
30. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/ TexCAPS
31. Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study
32. Serum cholesterol, blood pressure, and mortality: Implications from a cohort of 361 662 men
33. Communicating the risk reduction achieved by cholesterol reducing drugs
34. Lipid-lowering therapy in low-risk patients
35. Joint British recommendations on prevention of coronary heart disease in clinical practice
36. Need for large scale randomised evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF heart protection study and other major trials